David Price

David is currently Vice President, Research Site Head at Vertex Oxford. He is responsible for leading the site's scientific strategy and driving the discovery of new medicines. Prior to this role, David was Vice President of Medicine Design with Pfizer. He Joined Pfizer in 1998 and worked in a variety of therapeutic areas including anti-infectives, respiratory diseases, and internal medicine.

David studied for his Ph.D. at the University of Nottingham in the UK and then carried out postdoctoral research at Colorado State University with Prof. Al. Meyers directed toward the asymmetric synthesis of azasugars for the potential treatment of HIV. In 1998, David returned to the UK to take up a position as a Team Leader in Discovery Chemistry with Pfizer within the HIV research group. This was a fantastic learning environment and lead to the discovery of lersivirine and maraviroc which were key assets in the creation of the GSK/Pfizer joint venture company Viiv. In 2007, David moved to the USA and contributed to clinical candidates within internal medicine. In 2020 he returned to the UK for the exciting opportunity to lead the Oxford drug discovery community within Vertex.

David's most significant achievement has been the discovery of the marketed drug maraviroc (Selzentry®), which received FDA approval in 2007 for the treatment of HIV infection. David has published >90 peer-reviewed scientific articles and numerous patents. David has a consistent track record delivering medicines to the patients we serve.